Digital Diabetes Care Is Expanding Around GLP-1s. The Real Test Is Whether Support Extends Beyond the Prescription.
GLP-1 medicines are changing more than medication lists. They are changing the market for diabetes support. Employers, health plans, clinicians, and patients are all asking versions of the same question: if a person starts a GLP-1 medicine, what happens around the prescription? Who helps them understand side effects, protect nutrition, stay active, navigate coverage, monitor […]
Food Is Medicine Works Best When It Is Built Into Care—not Added as an Afterthought
“Food is medicine” is an appealing phrase because it names something many people living with type 2 diabetes already know: food choices are not a side note. They affect energy, glucose patterns, blood pressure, lipids, sleep, and the routines that make treatment sustainable. But the phrase can also become vague. Telling someone to “eat better” […]
A GLP-1 Prescription Is Not a Complete Care Plan: What Responsible Evaluation and Follow-Up Look Like
GLP-1 medicines have become a major part of conversations about weight, blood sugar, and metabolic health. That visibility has created opportunity: some people who once felt shut out of care are now asking better questions about diabetes, obesity, and long-term risk. It has also created a problem. A medication can be presented online as if […]
A One-Time Gene Therapy for Diabetic Retinopathy? What Is Known—and What Is Still Investigational
Diabetic retinopathy is a diabetes complication that affects the blood vessels of the retina, the light-sensitive tissue at the back of the eye. It can progress without noticeable symptoms in its early stages, which is why regular eye screening matters even when vision seems normal. A recent company announcement described follow-up results from a study […]
Akkermansia and Type 2 Diabetes: Promising Microbiome Science, Not a Supplement Prescription
The human gut contains a large and diverse community of microorganisms. Researchers are increasingly interested in how this ecosystem interacts with digestion, immune signaling, medications, body weight, and metabolic health. One bacterium that appears frequently in this research is Akkermansia muciniphila. Akkermansia lives in the mucus layer of the intestine and has been associated, in […]
Semaglutide and Fatty Liver Disease: What the MASH Evidence Actually Shows
Metabolic dysfunction-associated steatohepatitis, or MASH, is a form of fatty liver disease in which excess fat in the liver is accompanied by inflammation and liver-cell injury. Over time, some people develop fibrosis, or scarring, which can progress to cirrhosis and other serious complications. Why MASH matters in a type 2 diabetes conversation MASH is closely […]
GLP-1s After 60: Why Medication Decisions Must Protect Strength, Function, and Independence
Source note: This article was prompted by reporting on GLP-1 medicines and aging, plus a commentary on the history of weight-loss culture. The question is not simply “Will it cause weight loss?” GLP-1 receptor agonists have changed the conversation around obesity and type 2 diabetes. These medicines can improve glucose control in people with type […]
Type 2 Diabetes Remission Is a Clinical Goal—Not a Marketing Promise
A more useful conversation than “cure” versus “control” People living with type 2 diabetes deserve more than a conversation limited to “manage this forever” or, at the other extreme, “reverse it quickly.” A better conversation is about remission: a measurable clinical outcome that may be achievable for some people through an individualized, sustained approach to […]
Diabetes and Depression Just Got Linked in a New Way
A 2026 meta-analysis published in Frontiers in Medicine and supported by a NYU nursing report and a 2026 PubMed-listed review found that Type 2 diabetes and depression share a stronger bidirectional relationship than previously understood — adults with depression have a 60% higher risk of developing Type 2 diabetes, and adults with Type 2 diabetes […]
Beta Cells May Need Rhythmic Rest to Function.
New lab research published this month suggests that rhythmic “rest breaks” in pancreatic beta cells help preserve insulin-producing function in Type 2 diabetes, rather than continuously stimulating them. The study, reported by Ohio University researchers and detailed in Science Daily coverage, showed better glucose sensing, improved calcium signaling, and lower cellular stress when beta cells […]